HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer

Rinath Jeselsohn; Kornelia Polyak

doi:10.1016/j.chembiol.2023.08.006

HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer

Cell Chem Biol. 2023 Oct 19;30(10):1183-1185. doi: 10.1016/j.chembiol.2023.08.006.

Authors

Rinath Jeselsohn¹, Kornelia Polyak²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.

PMID: 37863030
DOI: 10.1016/j.chembiol.2023.08.006

Abstract

Inhibitors for the KAT6 family of histone acetyltransferases (HATs) have been actively pursued due to the oncogenic roles of KAT6A in human cancer. CTx-648 is a novel KAT6A/B inhibitor with excellent pharmacokinetic properties and in vivo efficacy that represents a promising new treatment strategy for estrogen-receptor-positive breast cancer.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Breast Neoplasms* / drug therapy
Estrogens
Female
Histone Acetyltransferases
Humans

Substances

Histone Acetyltransferases
Estrogens
KAT6A protein, human

Abstract

Publication types

MeSH terms

Substances

Grants and funding